Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-4538 in advanced or recurrent solid tumors
NCT02261298Phase 1Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Oct 2014
- Primary completion
- Jun 2015
- Countries
- 1
01
Overview
Phase 1, open-label trial of nivolumab in solid tumor (advanced stage) and Not applicable (3 arms), sponsored by Ono Pharmaceutical. Primary endpoints: Adverse Events at 6 months, Number of deaths at 6 months and 3 more. Started Oct 2014; status: completed.
02
Drugs
03
Conditions
solid tumor (advanced stage)Not applicable
Beyond the preview
Go deeper on NCT02261298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02261298.